-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plocabulin in Germ Cell Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plocabulin in Germ Cell Tumors report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plocabulin in Germ Cell Tumors Drug Details: Plocabulin (PM-184, PM-060184) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plocabulin in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plocabulin in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plocabulin in Fallopian Tube Cancer Drug Details: Plocabulin (PM-184, PM-060184) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plocabulin in Transitional Cell Cancer (Urothelial Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plocabulin in Transitional Cell Cancer (Urothelial Cell Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plocabulin in Transitional Cell Cancer (Urothelial Cell Cancer)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plocabulin in Biliary Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plocabulin in Biliary Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plocabulin in Biliary Tumor Drug Details: Plocabulin (PM-184, PM-060184) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plocabulin in Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plocabulin in Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plocabulin in Adenocarcinoma Drug Details: Plocabulin (PM-184, PM-060184) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plocabulin in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plocabulin in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plocabulin in Peritoneal Cancer Drug Details: Plocabulin (PM-184, PM-060184) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plocabulin in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plocabulin in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plocabulin in Epithelial Ovarian Cancer Drug Details: Plocabulin (PM-184, PM-060184) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Plocabulin in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plocabulin in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plocabulin in Breast Cancer Drug Details: Plocabulin (PM-184, PM-060184) is under development...
-
Analyst Opinions
Adaptogens in Non-Alcoholic Beverages – Industry Insights
Adaptogens can drive and facilitate the demands for more functional, health-oriented, and innovative non-alcoholic drinks. However, brands will need to consider how to position these products, since the effectiveness of adaptogens as an ingredient category and the functionalities that these substances provide might be questioned due to the ongoing nature of associated research and the propensity for consumer skepticism. One of the new ingredient groups which is rapidly gaining popularity in the market for non-alcoholic drinks is adaptogens. Adaptogens are...
-
Product Insights
PMS 3 Solar PV Park
PMS 3 Solar PV Park is a solar PV project located in Grand Est, France. The project is owned by Pays de Montmedy Solaire 3 Sarl and was developed by Enerparc AG. The project came online in 2021. Empower your strategies with our PMS 3 Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the...